• Start
  • Cancer
  • Technology
    • Technology
    • Human Scaffolds
    • 3D Synthetic Scaffolds
  • Products & Services
  • Pipeline
  • News
  • Publications
  • Partners & Customers
  • About
Curing cancer by generating precision medicine Curing cancer by generating precision medicine Curing cancer by generating precision medicine Curing cancer by generating precision medicine
  • Start
  • Cancer
  • Technology
    • Technology
    • Human Scaffolds
    • 3D Synthetic Scaffolds
  • Products & Services
  • Pipeline
  • News
  • Publications
  • Partners & Customers
  • About

Archives

Monthly Archive for: "May, 2022"
Home » Archives for May 2022
INTELLECTUAL PROPERTY 2
0
By Per Setterberg
In News, Publication
Posted May 18, 2022

INTELLECTUAL PROPERTY 2

Published patent application for the use of patient derived scaffolds within immune-oncology The patent application covers the use of cell-free scaffolds  as a predictive tool in assessing cancer [...]

READ MORE
9. Breast Cancer Patient-Derived Scaffolds Can Expose Unique Individual Cancer Progressing Properties
0
By Per Setterberg
In Publication
Posted May 4, 2022

9. Breast Cancer Patient-Derived Scaffolds Can Expose Unique Individual Cancer Progressing Properties

Breast Cancer Patient-Derived Scaffolds Can Expose Unique Individual Cancer Progressing Properties of the Cancer Microenvironment Associated with Clinical Characteristics [...]

READ MORE
SLAS podcast on pre-clinical drug screening
0
By Per Setterberg
In News
Posted May 3, 2022

SLAS podcast on pre-clinical drug screening

Iscaffpharma interviewed on the importance of human microenvironment for pre-clinical drug screening. Listen here

READ MORE
Recent Posts
  • Business Developer
    Business Developer
    May 1, 2024
  • Iscaffpharma’s first patent issued by the United States Patent and Trademark Office
    Iscaffpharma’s first patent issued by the United States Patent and Trademark Office
    January 26, 2024
  • SLAS honors Per Setterberg as fellow member
    SLAS honors Per Setterberg as fellow member
    October 19, 2023
Recent Publications
  • 17. Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells
    17. Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells
    December 16, 2024
  • 16. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development
    16. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development
    April 26, 2024
  • 15. Proteomics of cell-free breast cancer scaffolds identify clinically relevant imprinted proteins and cancer-progressing properties
    15. Proteomics of cell-free breast cancer scaffolds identify clinically relevant imprinted proteins and cancer-progressing properties
    April 4, 2024
Contact us
  • Org nr: 559120-9753
  • Iscaff Pharma AB
    Erik Dahlbergsgatan 11A
    411 26 Gothenburg
    Sweden
  • contact@iscaffpharma.com
Copyright All Rights Reserved © 2023
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt